CL2016000219A1 - Proteinas de fusión terapéutica. - Google Patents

Proteinas de fusión terapéutica.

Info

Publication number: CL2016000219A1
Authority: CL; Chile
Prior art keywords: fusion proteins; therapeutic fusion; therapeutic; proteins; fusion
Prior art date: 2013-08-02

Application number

CL2016000219A

Other languages

English (en)

Inventor

Hendrik Knoetgen

Jens Niewoehner

Bernd Bohrmann

Per-Ola Freskgard

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-02

Filing date

2016-01-28

Publication date

2016-09-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48900891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000219(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-01-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2016-09-16 Publication of CL2016000219A1 publication Critical patent/CL2016000219A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

CL2016000219A 2013-08-02 2016-01-28 Proteinas de fusión terapéutica. CL2016000219A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP13179056		2013-08-02

Publications (1)

Publication Number	Publication Date
CL2016000219A1 true CL2016000219A1 (es)	2016-09-16

Family

ID=48900891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2016000219A CL2016000219A1 (es)	2013-08-02	2016-01-28	Proteinas de fusión terapéutica.

Country Status (20)

Country	Link
US (1)	US20160168253A1 (es)
EP (1)	EP3027280A1 (es)
JP (1)	JP2016527260A (es)
KR (1)	KR20160037173A (es)
CN (1)	CN105431203A (es)
AU (1)	AU2014298519A1 (es)
BR (1)	BR112016001782A2 (es)
CA (1)	CA2919325A1 (es)
CL (1)	CL2016000219A1 (es)
CR (1)	CR20160041A (es)
EA (1)	EA201600141A1 (es)
HK (1)	HK1216159A1 (es)
IL (1)	IL243353A0 (es)
MA (1)	MA38797A1 (es)
MX (1)	MX2016001145A (es)
PE (1)	PE20160720A1 (es)
PH (1)	PH12016500123A1 (es)
SG (1)	SG11201600807YA (es)
WO (1)	WO2015014884A1 (es)
ZA (1)	ZA201600086B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012018790A2 (en)	2010-08-03	2012-02-09	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112017027965A2 (pt)	2015-06-24	2018-08-28	Japan Chem Res	anticorpo receptor, proteína de fusão, fragmento de dna, vetor de expressão, célula, complexo de anticorpo receptor, usos de um anticorpo receptor e de uma proteína de fusão, e, métodos para tratamento de um distúrbio e de uma doença.
WO2016207245A1 (en) *	2015-06-24	2016-12-29	F. Hoffmann-La Roche Ag	Humanized anti-tau(ps422) antibodies and methods of use
PE20180602A1 (es)	2015-06-24	2018-04-09	Hoffmann La Roche	Anticuerpos anti-receptor de transferrina con afinidad disenada
EP3315515A4 (en)	2015-06-24	2019-06-05	JCR Pharmaceuticals Co., Ltd.	HYBRID PROTEIN CONTAINING A BDNF
AR106189A1 (es) *	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja)	2015-10-02	2020-03-04	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
NZ752703A (en)	2016-12-26	2022-09-30	Japan Chem Res	Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
US10457717B2 (en)	2017-02-17	2019-10-29	Denali Therapeutics Inc.	Engineered polypeptides
ES2932759T3 (es)	2017-02-17	2023-01-25	Denali Therapeutics Inc	Polipéptidos de unión al receptor de transferrina diseñados
US10143187B2 (en)	2017-02-17	2018-12-04	Denali Therapeutics Inc.	Transferrin receptor transgenic models
WO2024169990A1 (zh) *	2023-02-13	2024-08-22	浙江大学绍兴研究院	双特异性抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1934341A1 (en) *	2005-10-03	2008-06-25	AstraZeneca AB	Fusion proteins having a modulated half-life in plasma
CA2661042C (en) *	2006-08-18	2012-12-11	Armagen Technologies, Inc.	Agents for blood-brain barrier delivery
TW200907056A (en) *	2007-03-28	2009-02-16	Astrazeneca Ab	New method
WO2008135380A1 (en) *	2007-05-02	2008-11-13	F. Hoffmann-La Roche Ag	Method for stabilizing a protein
WO2010037135A2 (en) *	2008-09-29	2010-04-01	The Regents Of The University Of California	Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
WO2011160732A1 (en) *	2010-06-21	2011-12-29	Medimmune, Llc.	Protease variants of human neprilysin
AU2011336716B2 (en) *	2010-11-30	2016-01-21	Genentech, Inc.	Low affinity blood brain barrier receptor antibodies and uses therefor

2014
- 2014-07-30 BR BR112016001782A patent/BR112016001782A2/pt not_active Application Discontinuation
- 2014-07-30 AU AU2014298519A patent/AU2014298519A1/en not_active Abandoned
- 2014-07-30 EP EP14747595.8A patent/EP3027280A1/en not_active Withdrawn
- 2014-07-30 US US14/907,173 patent/US20160168253A1/en not_active Abandoned
- 2014-07-30 PE PE2016000199A patent/PE20160720A1/es unknown
- 2014-07-30 JP JP2016530511A patent/JP2016527260A/ja active Pending
- 2014-07-30 CA CA2919325A patent/CA2919325A1/en not_active Abandoned
- 2014-07-30 MA MA38797A patent/MA38797A1/fr unknown
- 2014-07-30 WO PCT/EP2014/066355 patent/WO2015014884A1/en active Application Filing
- 2014-07-30 KR KR1020167002488A patent/KR20160037173A/ko not_active Application Discontinuation
- 2014-07-30 CN CN201480043474.2A patent/CN105431203A/zh active Pending
- 2014-07-30 MX MX2016001145A patent/MX2016001145A/es unknown
- 2014-07-30 SG SG11201600807YA patent/SG11201600807YA/en unknown
- 2014-07-30 EA EA201600141A patent/EA201600141A1/ru unknown
2015
- 2015-12-24 IL IL243353A patent/IL243353A0/en unknown
2016
- 2016-01-06 ZA ZA2016/00086A patent/ZA201600086B/en unknown
- 2016-01-19 PH PH12016500123A patent/PH12016500123A1/en unknown
- 2016-01-20 CR CR20160041A patent/CR20160041A/es unknown
- 2016-01-28 CL CL2016000219A patent/CL2016000219A1/es unknown
- 2016-04-08 HK HK16104037.9A patent/HK1216159A1/zh unknown

Also Published As

Publication number	Publication date
US20160168253A1 (en)	2016-06-16
EP3027280A1 (en)	2016-06-08
PH12016500123A1 (en)	2016-04-25
CA2919325A1 (en)	2015-02-05
IL243353A0 (en)	2016-02-29
JP2016527260A (ja)	2016-09-08
KR20160037173A (ko)	2016-04-05
CN105431203A (zh)	2016-03-23
WO2015014884A1 (en)	2015-02-05
HK1216159A1 (zh)	2016-10-21
EA201600141A1 (ru)	2016-09-30
ZA201600086B (en)	2017-04-26
CR20160041A (es)	2016-02-08
PE20160720A1 (es)	2016-07-28
MA38797A1 (fr)	2018-06-29
SG11201600807YA (en)	2016-03-30
AU2014298519A1 (en)	2016-02-04
BR112016001782A2 (pt)	2017-08-29
MX2016001145A (es)	2016-04-29

Publication	Publication Date	Title
DK3292141T3 (da)	2020-04-20	Fusionsproteiner
CL2016000219A1 (es)	2016-09-16	Proteinas de fusión terapéutica.
DK3180363T3 (da)	2019-11-04	Sirp-alpha-immunoglobulin fusionsproteiner
DK2951203T3 (da)	2019-08-12	Heterodimere proteiner
CL2016000680A1 (es)	2016-12-23	Formulaciones de anticuerpos anti-pdl1.
FR3006466B3 (fr)	2015-10-30	.
HRP20190434T1 (hr)	2019-04-19	Fuzijski protein
BR302014001378S1 (pt)	2015-05-19	Configuração aplicada em bolsa.
DK3041857T3 (da)	2019-07-22	Protein a-kromatografi
DK3107562T3 (da)	2019-12-16	P97-ids-fusionsproteiner
BR112016000140A2 (pt)	2017-07-25	Articulação ortésica
FR3007989B1 (fr)	2016-01-01	Autoinjecteur.
FR3013601B1 (fr)	2017-08-11	Autoinjecteur.
HK1231494A1 (zh)	2017-12-22	殺蟲融合蛋白改進
HK1220903A1 (zh)	2017-05-19	軟骨結合型融合蛋白
CL2016002136A1 (es)	2017-08-11	Proteinas de fusión uti
EP2969009A4 (en)	2016-11-02	MODIFIED FC FUSION PROTEINS
GB201308057D0 (en)	2013-06-12	Protein
FR3001302B1 (fr)	2016-01-22	.
CR20180079A (es)	2018-04-24	Moléculas de fusión
DK3089990T3 (da)	2020-08-24	Forbedret proteinekspression
GB201401955D0 (en)	2014-03-19	Protein
FR3001303B1 (fr)	2015-07-31	.
DK3089991T3 (da)	2019-12-02	Forbedret proteinekspression
FR3014440B1 (fr)	2016-01-22	Polypeptides entomotoxiques